Johnson & Johnson (JNJ)vsNovo Nordisk A/S (NVO)
JNJ
Johnson & Johnson
$270.47
+1.25%
HEALTHCARE · Cap: $682.52B
NVO
Novo Nordisk A/S
$37.82
-2.70%
HEALTHCARE · Cap: $177.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 236% more annual revenue ($333.65B vs $99.33B). NVO leads profitability with a 33.9% profit margin vs 16.2%. JNJ appears more attractively valued with a PEG of 3.16. NVO earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy54
out of 100
Grade: C-
NVO
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-84.0%
Fair Value
$145.14
Current Price
$270.47
$125.33 premium
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 52 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 40.1%
Generating 28.1B in free cash flow
Large-cap with strong market position
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 95.9%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 15.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.9% and operating margin at 40.1%.
Bear Case : JNJ
The primary concerns for JNJ are Piotroski F-Score, PEG Ratio, P/E Ratio. A P/E of 43.0x leaves little room for execution misses.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
NVO carries more volatility with a beta of 0.37 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
NVO generates stronger free cash flow (28.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVO scores higher overall (59/100 vs 54/100), backed by strong 33.9% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?